SRR1364739
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1339968 | GTEX | — | 0.943 |
| 2 | SRR1491293 | GTEX | — | 0.943 |
| 3 | SRR1375203 | GTEX | — | 0.934 |
| 4 | SRR1335707 | GTEX | — | 0.933 |
| 5 | SRR1458180 | GTEX | — | 0.926 |
| 6 | SRR607538 | GTEX | — | 0.917 |
| 7 | ERR2598336 | fetal | fetal | 0.913 |
| 8 | SRR1391598 | GTEX | — | 0.911 |
| 9 | SRR1082759 | GTEX | — | 0.911 |
| 10 | SRR1345478 | GTEX | — | 0.910 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.393 | Inavolisib | — uncovered |
| COAGULATION | 0.383 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.355 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.334 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.296 | Inavolisib | — uncovered |
| MYOGENESIS | 0.292 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.276 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.264 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.232 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.215 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.211 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.202 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.184 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.177 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.177 | Inavolisib | — uncovered |
| COMPLEMENT | 0.159 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.158 | Idelalisib | — uncovered |
| APOPTOSIS | 0.155 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.135 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.126 | Remibrutinib | — uncovered |